Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03IKZ
|
||||
| Former ID |
DIB000970
|
||||
| Drug Name |
HBP-347
|
||||
| Synonyms |
HBP-347 (oral, cancer/autoimmunity/ocular disease); Hypericin (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; HBP-347 (oral, cancer/autoimmunity/ocular disease), Hy BioPharma; Hypericin (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University; HBP-347 (oral, cancer/autoimmunity/ocular disease), Weizmann Institute/New York University
|
||||
| Indication | Autoimmune diabetes [ICD10:E08-E13] | Discontinued in Phase 3 | [550048] | ||
| Company |
Weizmann Institute of Science
|
||||
| Target and Pathway | |||||
| Target(s) | Heat shock protein HSP90 | Target Info | Modulator | [550909] | |
| References | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.